31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In this cohort, APOE ε4 carrier status was related to disease severity at baseline rather than to the rate of cognitive decline over 80 weeks. 3 key findings →
Design: clinical trial Participants: 370 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Amyloid plaques, one of the defining features of Alzheimer’s disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The cost-effectiveness of ATTs is strongly influenced by the waning of the treatment effect. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Biases in cognitive/functional screening tests may disproportionately exclude ethnoracial minorities in AD prevention trials. 1 key finding →
Participants: 6,669 Evidence: low
Full summary, score breakdown and related studies → Original source
NODDI-derived ODI is associated with tau PET signal, even in preclinical disease and may discriminate individuals with-and without tau beyond the MTL. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These therapies require complex diagnostic workup and safety monitoring, raising significant budget impact concerns for healthcare payers. 2 key findings →
Participants: 11,568 Evidence: low
Full summary, score breakdown and related studies → Original source
The overall incidence of any ARIA was 25.2%, with ARIA-H occurring in 22.4% of patients and ARIA-E in 12.2%. 3 key findings →
Design: cohort study Participants: 468 Evidence: moderate
Full summary, score breakdown and related studies → Original source
MCH-Guard offers a flexible clinical decision-support tool for optimizing spontaneous MCH & ARIA surveillance. 1 key finding →
Design: longitudinal study Participants: 813 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of haemorrhagic risk in Alzheimer’s disease. 2 key findings →
Participants: 1,069 Evidence: low
Full summary, score breakdown and related studies → Original source
We trained a self-configuring nnU-Net model for CMB segmentation in a hetero-geneous multicenter sample ( n =264), including 1.5T and 3T field strengths, SWI and T2*-GRE sequences, and community and clinical cohorts. 1 key finding →
Participants: 264 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study examined the safety and tolerability of centralized lecanemab administration across a widely distributed region and suggests that use of distributed infusion sites increases access to disease-modifying treatment without significant increase in risk. 2 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source
The complete absence of ARIA distinguishes XPro1595 from amyloid-targeting therapies and supports its potential for use in combination strategies and potentially for those at a higher risk of ARIA. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
A bstract INTRODUCTION Treatment response in Alzheimer’s disease (AD) varies substantially across patients, yet no validated frameworks exist to estimate heterogeneous treatment effects (HTE) from observational data while controlling for confounding bias. 2 key findings →
Participants: 4,049 Evidence: low
Full summary, score breakdown and related studies → Original source
High placebo response is an obstacle in developing drugs to treat agitation in Alzheimer’s disease (AAD), a prevalent and burdensome symptom. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings confirm the diagnostic value of urinary β-amyloid protein detection in MCI and AD-related dementia. 5 key findings →
Design: case-control study Participants: 51,187 Evidence: high
Full summary, score breakdown and related studies → Original source
The administration of mAbs that specifically target the N-terminus of Aβ showed promising results in reducing Aβ burden and ameliorating cognitive decline. 5 key findings →
Design: systematic review Participants: 34 Evidence: high
Full summary, score breakdown and related studies → Original source
Amyloid-related imaging abnormalities (ARIA) remain the principal safety concern limiting adoption of anti-amyloid therapies such as lecanemab, yet their underlying biology is poorly defined. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Apolipoprotein E (APOE) e4 and e2 alleles are respectively the most risk increasing and risk decreasing, common genetic risk factors for Alzheimer’s disease (AD) 1,2 . 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We report the case of an elderly woman in good general health aside from early-stage Alzheimer’s disease who was enrolled in a randomized controlled trial of the novel therapeutic monoclonal antibody lecanemab where she was treated with the placebo, and subsequently in the open label extension study where she received lecanemab infusions every two weeks. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
After Aβ immunotherapy, capCAA was increased, likely reflecting the drainage of soluble Aβ towards the vasculature and providing a potential mechanism to disrupt AQP4-containing astrocyte endfeet, resulting in ARIA-E. We did not identify alterations in AQP4, potentially because of limitations in the timing of the post-mortem analysis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events